Last reviewed 2026-05-31 · How we verify

Rapid optimized analgesic strategy

Assistance Publique - Hôpitaux de Paris · Phase 1 active Small molecule ✓ Verified May 2026

Rapid optimized analgesic strategy is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 1 development.

A rapid optimized analgesic strategy has been studied in clinical trials for conditions such as Sickle Cell Anemia, comparing it to the current analgesic strategy. The strategy involves a combination of medications including nitrous oxide, nefopam, acetaminophen, and morphine, which are small molecule compounds.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Rapid optimized analgesic strategy
Sponsor	Assistance Publique - Hôpitaux de Paris
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rapid optimized analgesic strategy CI brief — competitive landscape report
Rapid optimized analgesic strategy updates RSS · CI watch RSS
Assistance Publique - Hôpitaux de Paris portfolio CI

Frequently asked questions about Rapid optimized analgesic strategy

What is Rapid optimized analgesic strategy?

Rapid optimized analgesic strategy is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.

Who makes Rapid optimized analgesic strategy?

Rapid optimized analgesic strategy is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

What development phase is Rapid optimized analgesic strategy in?

Rapid optimized analgesic strategy is in Phase 1.

Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing